Hematologic Malignancies – Expert Insights from Charles Craddock

Expert Interview

Professor Craddock discusses three hematology-oncology abstracts from the ASCO21 Annual Meeting reporting on the use of letermovir to prevent cytomegalovirus reactions in allogeneic stem cell transplant recipients with graft versus host disease (abstract 7004), first-line asparcytarabine in acute myeloid leukemia patients unfit for standard chemotherapy, and the initial results from the V-FAST trial of CPX-351 plus targeted agents for newly diagnosed acute myeloid leukemia.
Interviewee: Charles Craddock, CBE, FRCP, FRCPath, DPhil
Affiliation(s): Queen Elizabeth Hospital, University of Birmingham, UK
Disclosures: Honoraria: Abbvie, Celgene, Jazz Pharmaceuticals, Janssen, Pfizer, Daiichi Sankyo, Amgen, Astellas Pharma; Consulting or Advisory Role: Daiichi Sankyo, Abbvie, Janssen, Novartis, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Daiichi Sankyo, Eurocept; Speakers' Bureau: Abbvie, Janssen, Novartis, Roche, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Daiichi Sankyo, Eurocept; Research Funding: Celgene, Jazz Pharmaceuticals, Kite Pharma, Jazz Pharmaceuticals; Expert Testimony: Daiichi Sankyo; Travel, Accommodations, Expenses: Celgene, Jazz Pharmaceuticals, Daiichi Sankyo
Interview Date: June 8, 2021
Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Read full disclaimer here.
Share:
Share on facebook
Share on twitter
Share on linkedin

Abstracts Referenced In This Expert Interview

Oral Abstract Session

Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease

Presenter: Delaney Wolfe
Presentation Date: June 4, 2021
Abstract Number: 7004
Oral Abstract Session

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy

Presenter: Jessica K. Altman, MD
Presentation Date: June 4, 2021
Abstract Number: 7007
Oral Abstract Session

Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study

Presenter: Efstathios Kastritis, MD
Presentation Date: June 8, 2021
Abstract Number: 8003

Other Hematologic Malignancies Content

Poster Session

Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML

Presenter: Vinod Pullarkat, MD, MRCP
Presentation Date: June 4, 2021
Abstract Number: 7026
Expert Interview

Hematologic Malignancies – Expert Insights

Dr Berdeja discusses ASCO21 highlights for multiple myeloma, including updated results from the phase III ANDROMEDA study (abstract 8003), interim analysis of CASSIOPEIA, daratumumab maintenance vs observation (abstract 8004), updated results on ciltacabtagene autoleucel CAR-T therapy from CARTITUDE-1 (abstract 8005), results of a trial with bi-specific agent elranatamab (abstract 8006) and study of bi-specific agent teclistamab (abstract 8007) and of talquetamab in relapsed/refractory MM (abstract 8008) and updated results from the pivotal KarMMa study (abstract 8016).
Interviewee: Jesus G. Berdeja, MD
Interview Date: June 8, 2021
Expert Interview

Hematologic Malignancies – Expert Insights

Dr Shah discusses her ASCO21 highlights for multiple myeloma, including interim analysis of CASSIOPEIA, part 2-- daratumumab maintenance vs observation (abstract 8004), updated results on ciltacabtagene autoleucel CAR-T therapy from CARTITUDE-1 (abstract 8005), and results of recommended phase 2 dose in the first in-human phase 1 study of teclistamab (abstract 8007) and of talquetamab in relapsed/refractory MM (abstract 8008).
Interviewee: Nina Shah, MD
Interview Date: June 8, 2021
Oral Abstract Session

Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease

Presenter: Delaney Wolfe
Presentation Date: June 4, 2021
Abstract Number: 7004
Oral Abstract Session

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy

Presenter: Jessica K. Altman, MD
Presentation Date: June 4, 2021
Abstract Number: 7007
Oral Abstract Session

Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study

Presenter: Efstathios Kastritis, MD
Presentation Date: June 8, 2021
Abstract Number: 8003
Oral Abstract Session

Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2

Presenter: Philippe Moreau, MD
Presentation Date: June 8, 2021
Abstract Number: 8004
Oral Abstract Session

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1

Presenter: Saad Zafar Usmani, FACP, MBA, MD
Presentation Date: June 8, 2021
Abstract Number: 8005
Oral Abstract Session

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)

Presenter: Nizar J. Bahlis, MD
Presentation Date: June 8, 2021
Abstract Number: 8006
Oral Abstract Session

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM)

Presenter: Amrita Y. Krishnan, MD
Presentation Date: June 8, 2021
Abstract Number: 8007
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare